Adecatumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EpCAM |
| Clinical data | |
| Identifiers | |
503605-66-1  | |
| None | |
| Chemical data | |
| Formula | C6552H10080N1740O2052S46 |
| 147.5 kDa | |
| (what is this?) (verify) | |
Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326).
Adecatumumab has been used in clinical studies of treatment in prostate[1] and breast cancers.[2]
References
- ↑ Oberneder R, Weckermann D, Ebner B et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". Eur. J. Cancer 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989.
- ↑ Prang N, Preithner S, Brischwein K et al. (January 2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". Br. J. Cancer 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858. PMID 15655555.